TRIP11 as a Radioligand Therapy Target
TRIP11, thyroid hormone receptor interactor 11, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, TRIP11 staining is highest in head and neck cancer (100% of samples positive), lymphoma (100% of samples positive) and breast cancer (100% of samples positive). Evidence on whether TRIP11 internalizes is mixed. Clinical status: Discovery-stage (no clinical drug program).
Is TRIP11 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in head and neck cancer, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
TRIP11 expression in cancer
Protein expression of TRIP11 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Head and Neck Cancer | 1.00 | High | 100% |
| Lymphoma | 1.00 | High | 100% |
| Breast Cancer | 1.00 | High | 100% |
| Thyroid Cancer | 1.00 | High | 100% |
| Testicular Cancer | 0.97 | High | 100% |
| Colorectal Cancer | 0.97 | High | 100% |
| Glioma | 0.94 | High | 100% |
| Ovarian Cancer | 0.92 | High | 100% |
| Neuroendocrine Tumors | 0.92 | High | 100% |
| Cervical Cancer | 0.87 | High | 100% |
| Prostate Cancer | 0.87 | High | 100% |
| Endometrial Cancer | 0.86 | High | 92% |
| Bladder Cancer | 0.83 | High | 92% |
| Melanoma | 0.73 | High | 100% |
| Skin Cancer | 0.67 | High | 92% |
| Gastric Cancer | 0.64 | High | 92% |
| Lung Cancer | 0.53 | High | 100% |
| Kidney Cancer | 0.50 | Medium | 75% |
| Pancreatic Cancer | 0.42 | Medium | 75% |
| Liver Cancer | 0.30 | Medium | 64% |
Is TRIP11 internalized?
Uncertain. Insufficient literature found.
TRIP11 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for TRIP11 yet. Search ClinicalTrials.gov for TRIP11 trials.
TRIP11 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See TRIP11 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
TRIP11 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.04 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related head and neck cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · SSTR2 · B7-H3 (CD276) · STEAP2 · Mesothelin (MSLN)
See all radioligand therapy targets in head and neck cancer.
See how TRIP11 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.